Xynomic Pharmaceuticals Holdings Debt 2024

Xynomic Pharmaceuticals Holdings Aktienanalyse

What does Xynomic Pharmaceuticals Holdings do?

Xynomic Pharmaceuticals Holdings Inc is a biopharmaceutical company based in New York City that focuses on the development and marketing of innovative cancer therapies. The company was founded in 2016 and has since become a leading player in the industry. In this post, we would like to tell you more about the history and business model of Xynomic Pharmaceuticals, as well as the various products that the company offers. History of Xynomic Pharmaceuticals Holdings Inc Xynomic Pharmaceuticals was founded in 2016 by an experienced team of pharmaceutical industry experts, including Dr. Peng Wang, the CEO of the company. The company's goal from the beginning was to develop and bring to market innovative cancer drugs to help patients around the world. The company has made significant progress since its inception and now has an impressive portfolio of cancer therapies. Business model of Xynomic Pharmaceuticals The business model of Xynomic Pharmaceuticals is focused on developing high-quality cancer therapies and bringing them to market. The company works closely with leading academic institutions and commercial partners to identify and explore innovative concepts for combating cancer. Xynomic Pharmaceuticals' products are designed to treat specific types of cancer and be tailored to the needs of patients worldwide. Products of Xynomic Pharmaceuticals Xynomic Pharmaceuticals' portfolio includes a variety of innovative cancer therapies tailored to different types of cancer. One example is the drug Abexinostat, which is currently in phase 3 clinical trials and is used to treat peripheral T-cell lymphoma (PTCL). Abexinostat is an oral medication that targets epigenetic enzymes involved in the development of cancer. The drug has the potential to extend the survival of patients with PTCL and is a promising new treatment option for this serious disease. Another product of Xynomic Pharmaceuticals is the drug XP-102, which is used to treat fatty liver diseases. Fatty liver disease, also known as non-alcoholic fatty liver disease (NAFLD), is a common condition that occurs due to factors such as obesity and diabetes. XP-102 has the potential to improve liver performance and treat this disease, which currently has no effective medical treatment. Conclusion Xynomic Pharmaceuticals Holdings Inc is a rising biopharmaceutical company that develops innovative cancer drugs. The company has made significant progress since its inception and has an impressive portfolio of cancer therapies. Xynomic Pharmaceuticals works closely with leading partners and academic institutions to develop and provide innovative cancer therapies. The company's products have the potential to change the lives of patients worldwide and offer new treatment options for serious diseases. Xynomic Pharmaceuticals Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Xynomic Pharmaceuticals Holdings's Debt Structure

Xynomic Pharmaceuticals Holdings's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Xynomic Pharmaceuticals Holdings's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Xynomic Pharmaceuticals Holdings’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Xynomic Pharmaceuticals Holdings’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Xynomic Pharmaceuticals Holdings stock

What is the debt of Xynomic Pharmaceuticals Holdings this year?

Xynomic Pharmaceuticals Holdings has a debt level of 0 USD this year.

What was the debt of Xynomic Pharmaceuticals Holdings compared to the previous year?

The debt of Xynomic Pharmaceuticals Holdings has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in Xynomic Pharmaceuticals Holdings?

High debt can pose a risk for investors of Xynomic Pharmaceuticals Holdings, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Xynomic Pharmaceuticals Holdings?

Low debt means that Xynomic Pharmaceuticals Holdings has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Xynomic Pharmaceuticals Holdings affect the company?

An increase in debt of Xynomic Pharmaceuticals Holdings can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Xynomic Pharmaceuticals Holdings affect the company?

A reduction in debt of Xynomic Pharmaceuticals Holdings can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Xynomic Pharmaceuticals Holdings?

Some factors that can influence the debt of Xynomic Pharmaceuticals Holdings include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Xynomic Pharmaceuticals Holdings so important for investors?

The debts of Xynomic Pharmaceuticals Holdings are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Xynomic Pharmaceuticals Holdings take to change the debt?

To change the debt, Xynomic Pharmaceuticals Holdings can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Xynomic Pharmaceuticals Holdings pay?

Over the past 12 months, Xynomic Pharmaceuticals Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xynomic Pharmaceuticals Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Xynomic Pharmaceuticals Holdings?

The current dividend yield of Xynomic Pharmaceuticals Holdings is .

When does Xynomic Pharmaceuticals Holdings pay dividends?

Xynomic Pharmaceuticals Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xynomic Pharmaceuticals Holdings?

Xynomic Pharmaceuticals Holdings paid dividends every year for the past 0 years.

What is the dividend of Xynomic Pharmaceuticals Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xynomic Pharmaceuticals Holdings located?

Xynomic Pharmaceuticals Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xynomic Pharmaceuticals Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xynomic Pharmaceuticals Holdings from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Xynomic Pharmaceuticals Holdings pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Xynomic Pharmaceuticals Holdings in the year 2023?

In the year 2023, Xynomic Pharmaceuticals Holdings distributed 0 USD as dividends.

In which currency does Xynomic Pharmaceuticals Holdings pay out the dividend?

The dividends of Xynomic Pharmaceuticals Holdings are distributed in USD.